Faiditus

Author Shares Young Woman's Inspiring Journey as she Moves Across the Globe in Search of New Beginnings

Retrieved on: 
Tuesday, November 14, 2023

EAST ELMHURST, N.Y., Nov. 14, 2023 /PRNewswire-PRWeb/ -- Sharing a glimpse of life in mid-fifties for a young immigrant woman, author Hortense M. Jenkins has released her seventh book, "Bellinda Bell."

Key Points: 
  • "Bellinda Bell" shares the story of 22-year-old Bellinda Simms, a strong-willed, temperamental, and fearless young woman who is accustomed to battling her way out of any situation.
  • As she boards a banana boat with other migrants and begins a three-week journey from Jamaica to South Hampton, England, in search of a new beginning, Bellinda has no idea what awaits her.
  • "I want readers to understand that the life you are born into is not your fault," Jenkins explains.
  • Jenkins plans to continue adding to her collection of family and God-focused stories in future books.

LUNGevity to Present Three Research Abstracts at 2022 World Lung Conference

Retrieved on: 
Tuesday, August 9, 2022

WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.  

Key Points: 
  • WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.
  • Lung cancer healthcare providers work hard to deliver quality care to patients but are one piece of the puzzle.
  • The three abstracts presented at WCLC 2022 reiterate the importance of integrating the patient and caregiver perspective in both clinical research and healthcare delivery.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

Informed Consent Forms for Lung Cancer Clinical Trials May be a Barrier to Informed Trial Participation

Retrieved on: 
Tuesday, August 9, 2022

VIENNA, Austria, Aug. 9, 2022 /PRNewswire-PRWeb/ -- Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Trial Participation

Key Points: 
  • They are written at a level that is too high for most patients, thus possibly impeding real informed consent, according to a report given today at the IASLC World Conference on Lung Cancer in Vienna.
  • The purpose of the informed consent form (ICF) is to outline risks and benefits of an interventional clinical trial to a patient.
  • King-Kallimanis and her colleagues conducted a multi-step project involving patients and caregivers, trialists, regulators, and clinical trial sponsors to streamline the informed consent process.
  • The 20 ICFs reviewed were from phases 1, 2, and 3 clinical trials covering predominantly non-small cell lung cancer -- 60% were global trials.